Immuneering (IMRX) CEO Adds to Stake with $50k Share Purchase

Rhea-AI Filing Summary

Immuneering Corporation (IMRX) – Form 4 insider transaction: On 06/18/2025, President, CEO, Director and 10% owner Benjamin J. Zeskind bought 21,000 shares of Class A common stock on the open market at a weighted-average price of $2.3878 per share (trades ranged $2.31-$2.44). The filing was signed on 06/20/2025.

Following the purchase, Zeskind directly owns 2,302,852 shares. In addition, an indirect holding of 894,927 shares is held by the Benjamin J. Zeskind 2020 Family Trust, for which his spouse serves as sole trustee. The transaction was coded “P” (open-market purchase), indicating an increase in ownership. The form does not reference any Rule 10b5-1 trading plan.

The purchase represents roughly 0.9% of Zeskind’s direct stake and signals continued insider support, but the absolute amount (≈$50 k) is modest relative to his existing 3.2 million-share economic interest.

Positive

• Open-market purchase by CEO can signal management’s confidence in IMRX’s prospects.
• No shares were sold; the transaction strictly increases insider ownership.

Negative

• Purchase size is small (~$50k) relative to existing 3.2 m-share holding, limiting its material impact.

Insights

Securities Analyst

TL;DR: Modest insider buy; signals confidence but immaterial to float or valuation.

While insider purchases generally convey positive sentiment, the 21,000-share buy equates to just ~$50k and <1% of Zeskind’s aggregate holdings. Given his existing 3.2 m-share position, the incremental economic exposure is minor and unlikely to influence market supply-demand. No option exercises or sales accompanied the move, so dilution is unaffected. The filing is informational rather than transformational; investors may see a modest psychological boost but fundamental valuation remains unchanged.

Insider Trade Summary

Net Buyer: 21,000 shares ($50,144)

Net Buy 2 txns

Insider Zeskind Benjamin J.

Role PRESIDENT AND CEO

Bought 21,000 shs ($50K)

Type	Security	Shares	Price	Value
Purchase	Class A Common Stock	21,000	$2.3878	$50K
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Class A Common Stock — 2,302,852 shares (Direct); Class A Common Stock — 894,927 shares (Indirect, See Foonote)

Footnotes (1)

1. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $2.31 to $2.44. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price. Held by the Benjamin J. Zeskind 2020 Family Trust, where Lisa Schwartz, Dr. Zeskind's spouse, serves as sole trustee.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zeskind Benjamin J.

(Last) (First) (Middle)

245 MAIN STREET

SECOND FLOOR

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immuneering Corp [ IMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND CEO

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/18/2025		P		21,000	A	$2.3878(1)	2,302,852	D
Class A Common Stock								894,927	I	See Foonote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $2.31 to $2.44. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.

2. Held by the Benjamin J. Zeskind 2020 Family Trust, where Lisa Schwartz, Dr. Zeskind's spouse, serves as sole trustee.

Remarks:

	/s/ Michael D. Bookman, Attorney-in-Fact for Benjamin J. Zeskind	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many IMRX shares did CEO Benjamin J. Zeskind purchase?

He bought 21,000 Class A common shares on 06/18/2025.

What was the average purchase price reported on the Form 4 for IMRX?

The weighted-average price was $2.3878 per share (range $2.31-$2.44).

How many IMRX shares does Zeskind now own directly and indirectly?

Direct holding: 2,302,852 shares; Indirect (family trust): 894,927 shares.

Did the filing indicate use of a Rule 10b5-1 trading plan?

No. The check box for Rule 10b5-1(c) was not marked, indicating no such plan.

Was this Form 4 a purchase or sale of IMRX shares?

It was an open-market purchase (transaction code "P").